Company intelligence / Profile preview
Tessa Therapeutics
Singapore, Singapore
- Ownership
- Private
- Development stage
- Other
01
Overview
The company's lead allogeneic cell therapy, TT11X, demonstrated a 79% overall response rate and 43% complete response rate in heavily pre-treated CD30-positive Hodgkin lymphoma patients in Phase 1 trials. The therapy was well-tolerated with no dose-limiting toxicities or evidence of graft-versus-host-disease. The company's autologous therapy TT11 showed a 57.1% complete response rate in patients with classical Hodgkin's lymphoma in Phase 2 trials[1][9].
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyCAR-T therapy
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Baylor College of MedicineU.S. National Cancer InstituteChina-Singapore Guangzhou Knowledge CityParker Institute for Cancer ImmunotherapyVyriad
Beyond the preview
Go deeper on Tessa Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tessa Therapeutics.